-
![2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer](/abs-image/US/2012/04/03/US08148392B2/abs.jpg.150x150.jpg)
1.发明授权2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer 有权2-吲哚基咪唑并[4,5-d]菲咯啉衍生物及其在治疗癌症中的应用公开(公告)号：US08148392B2
公开(公告)日：2012-04-03
申请号：US11915257
申请日：2006-05-25
Applicant: Mario Huesca , Aiping H. Young , Yoon Lee , Aye Aye Khine , Jim A. Wright , Lisa Lock , Raed Al-Qawasmeh
Inventor： Mario Huesca , Aiping H. Young , Yoon Lee , Aye Aye Khine , Jim A. Wright , Lisa Lock , Raed Al-Qawasmeh
IPC: A61K31/4745 , C07D471/12
CPC classification number: C07D471/14
Abstract: 2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula (I) and methods of using same in the treatment of cancer, in particular, solid cancers and leukemia are provided. Pharmaceutical compositions comprising the compounds are also provided.
Abstract translation: 提供式（I）的2-吲哚基咪唑并[4,5-d]菲咯啉化合物及其在治疗癌症中的用途，特别是固体癌症和白血病。 还提供了包含该化合物的药物组合物。
-
2.发明授权Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth 失效胰岛素样生长因子II反义寡核苷酸序列及其用于抑制细胞生长的方法公开(公告)号：US06417169B1
公开(公告)日：2002-07-09
申请号：US09295593
申请日：1999-04-22
Applicant: Jim A. Wright , Aiping H. Young , Yoon S. Lee
Inventor： Jim A. Wright , Aiping H. Young , Yoon S. Lee
IPC: C07H2104
CPC classification number: C12N15/1136 , A61K38/00 , C12N2310/111 , C12N2310/315
Abstract: This invention relates to oligonucleotides complementary to the IGF-II genes which modulate tumor cell growth in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
Abstract translation: 本发明涉及与调节哺乳动物肿瘤细胞生长的IGF-II基因互补的寡核苷酸。 本发明还涉及使用这些化合物抑制哺乳动物肿瘤细胞生长的方法。 本发明还涉及包含药学上可接受的赋形剂和有效量的本发明化合物的药物组合物。
-
公开(公告)号：US20110158936A1
公开(公告)日：2011-06-30
申请号：US11817914
申请日：2006-03-08
Applicant: Jim A. Wright , Aiping H. Young , Yoon Lee , Ming Yu Cao
Inventor： Jim A. Wright , Aiping H. Young , Yoon Lee , Ming Yu Cao
CPC classification number: A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
Abstract: The use of interleukin 17E to inhibit tumour growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumour growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
Abstract translation: 提供了白细胞介素17E在受试者中抑制肿瘤生长的用途。 作为白细胞介素17E多肽或编码白细胞介素17E多肽的多核苷酸，可以外源性地向受试者提供白细胞介素17E，或者可以通过刺激内源白细胞介素17E的产生来提供白细胞介素17E。 还提供了白细胞介素17E与一种或多种抗癌治疗剂组合用于抑制受试者中的肿瘤生长的用途。 抗癌疗法包括例如标准化学治疗药物，免疫治疗剂，辐射，基因治疗，激素操作和反义治疗。
-
4.发明申请SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE AND USES THEREOF 审中-公开抗干扰素还原酶的小干扰RNA分子及其用途公开(公告)号：US20100204305A1
公开(公告)日：2010-08-12
申请号：US12700563
申请日：2010-02-04
Applicant: Aiping H. YOUNG , Jim A. WRIGHT
Inventor： Aiping H. YOUNG , Jim A. WRIGHT
IPC: A61K31/713 , A61P35/00
CPC classification number: A61K31/713
Abstract: Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers.
Abstract translation: 提供了靶向哺乳动物核糖核苷酸还原酶基因并能够抑制其靶基因表达的小干扰RNA（siRNA）分子。 本发明的siRNA分子能够在体外和体内减弱肿瘤细胞生长和/或增殖，因此可用于减轻各种哺乳动物癌症的生长和/或转移。
-
5.发明申请Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer 审中-公开用于治疗癌症的组合治疗方法的反义寡核苷酸靶向核糖核苷酸重组酶R2及其用途公开(公告)号：US20080311126A1
公开(公告)日：2008-12-18
申请号：US10585772
申请日：2005-01-12
Applicant: Aiping H. Young , Jim A. Wright , Yoon Lee
Inventor： Aiping H. Young , Jim A. Wright , Yoon Lee
IPC: A61K39/395 , A61K31/7088 , A61K39/00 , A61P31/00
CPC classification number: C12N15/1137 , A61K31/7088 , A61K31/7125 , A61K38/2013 , A61K38/212 , A61K45/06 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/31 , A61K2300/00
Abstract: Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines, non-cytokine adjuvants, monoclonal antibodies and cancer vaccines. The combinations can further comprise one or more chemotherapeutic agents. Methods of treating cancer in a mammal using the combinations are also provided.
Abstract translation: 包含针对编码哺乳动物核糖核苷酸还原酶R2蛋白的基因的反义寡核苷酸和一种或多种免疫治疗剂如细胞因子，非细胞因子佐剂，单克隆抗体和癌症疫苗的组合产物。 组合可以进一步包含一种或多种化学治疗剂。 还提供了使用这些组合治疗哺乳动物癌症的方法。
-
Patent Agency Ranking
公开(公告)号：US06610539B1
公开(公告)日：2003-08-26
申请号：US09112580
申请日：1998-07-09
Applicant: Jim A. Wright , Aiping H. Young , Dominique Dugourd
Inventor： Jim A. Wright , Aiping H. Young , Dominique Dugourd
IPC: C07H2104
CPC classification number: C12N15/113 , A61K38/00 , C12N15/1137 , C12N2310/315
Abstract: This invention relates to antisense oligonucleotides which modulate the expression of the ribonucleotide reductase or the secA genes in microorganisms. This invention is also related to methods of using such oligonucleotides in inhibiting the growth of microorganisms. These antisense oligonucleotides are particularly useful in treating pathological conditions in mammals which are mediated by the growth of microorganisms.
Abstract translation: 本发明涉及在微生物中调节核糖核苷酸还原酶或secA基因表达的反义寡核苷酸。 本发明还涉及使用这种寡核苷酸抑制微生物生长的方法。 这些反义寡核苷酸特别可用于治疗由微生物生长介导的哺乳动物的病理状况。
-
7.发明授权Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth 失效与硫氧还蛋白或硫氧还蛋白还原酶基因互补的寡核苷酸序列及其使用方法调节细胞生长公开(公告)号：US06566514B1
公开(公告)日：2003-05-20
申请号：US09601144
申请日：2000-10-18
Applicant: Jim A. Wright , Aiping H. Young , Yoon S. Lee
Inventor： Jim A. Wright , Aiping H. Young , Yoon S. Lee
IPC: C07H2104
CPC classification number: C12N15/1137 , A61K38/00 , C12N2310/111 , C12N2310/315
Abstract: This invention relates to oligonucleotides complementary to the thioredoxin and thioredoxin reductase genes which modulate tumor cell growth in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
Abstract translation: 本发明涉及与硫氧还蛋白和硫氧还蛋白还原酶基因互补的寡核苷酸，其调节哺乳动物的肿瘤细胞生长。 本发明还涉及使用这些化合物抑制哺乳动物肿瘤细胞生长的方法。 本发明还涉及包含药学上可接受的赋形剂和有效量的本发明化合物的药物组合物。
-
8.发明授权
公开(公告)号：US6121000A
公开(公告)日：2000-09-19
申请号：US249730
申请日：1999-02-11
Applicant: Jim A. Wright , Aiping H. Young
Inventor： Jim A. Wright , Aiping H. Young
IPC: C12N15/09 , A61K31/711 , A61K48/00 , A61P35/00 , A61P35/04 , C12N15/113 , C12Q1/68 , C07H21/04 , C12N15/63
CPC classification number: C12N15/1137 , C12N2310/111
Abstract: Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
-
公开(公告)号：US08287851B2
公开(公告)日：2012-10-16
申请号：US11817914
申请日：2006-03-08
Applicant: Jim A. Wright , Aiping H. Young , Yoon Lee , Ming Yu Cao
Inventor： Jim A. Wright , Aiping H. Young , Yoon Lee , Ming Yu Cao
IPC: A61K38/20
CPC classification number: A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
Abstract: The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
Abstract translation: 提供了白细胞介素17E在受试者中抑制肿瘤生长的用途。 作为白细胞介素17E多肽或编码白细胞介素17E多肽的多核苷酸，可以外源性地向受试者提供白细胞介素17E，或者可以通过刺激内源白细胞介素17E的产生来提供白细胞介素17E。 还提供了白细胞介素17E与一种或多种抗癌治疗剂组合用于抑制受试者中的肿瘤生长的用途。 抗癌疗法包括例如标准化学治疗药物，免疫治疗剂，辐射，基因治疗，激素操作和反义治疗。
-
10.发明授权Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer 失效针对核糖核苷酸还原酶R2的反义寡核苷酸及其在治疗癌症中的用途公开(公告)号：US07968526B2
公开(公告)日：2011-06-28
申请号：US12691664
申请日：2010-01-21
Applicant: Jim A. Wright , Aiping H. Young
Inventor： Jim A. Wright , Aiping H. Young
CPC classification number: C12N15/1137 , A61K31/19 , A61K31/4745 , A61K31/573 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , C12N2310/315
Abstract: The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.
Abstract translation: 本发明提供了针对哺乳动物核糖核苷酸还原酶R2基因的反义寡核苷酸以及反义寡核苷酸与一种或多种用于治疗癌症的化学治疗剂的组合。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.034 seconds)
